logo
Plus   Neg
Share
Email

Tesco Names Jason Tarry CEO Of UK & ROI, Replacing Charles Wilson

Tesco plc (TSCO.L,TSCDY.PK) announced Tuesday that Jason Tarry, currently Group Chief Product Officer, will become the CEO of the UK & ROI business. Andrew Yaxley, currently CEO Ireland, will be promoted to Group Chief Product Officer and join the Tesco Executive Committee.

Both Jason and Andrew will report to Dave Lewis.

Tarry replaces Charles Wilson, who will step down as CEO Tesco UK & ROI and from the PLC Board, but remain on the Tesco Executive Committee.

All changes to responsibilities will be effective from July 16.

The company noted that Wilson was diagnosed with throat cancer and has responded very well to the treatment and all the signs are that the treatment has been successful.

However, given the nature of the illness and the need for him to remain vigilant in his recuperation, the company said it has agreed to make the changes within the senior leadership team.

Wilson will focus on leading the Booker business, continuing to deliver the cost synergies and driving the growth agenda set out in the merger agreement. As a member of the Executive Committee he will contribute to the broader Tesco UK Strategy. He will continue to report to Dave Lewis.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT